SEC Form 4 · accession 0001104659-15-005927
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sanofi
10% Owner
Period of report
Jan 29, 2015
Accepted (ET)
Feb 2, 2015 · 1:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 29, 2015 | P | 97,118 | $95.00 | A | 10,051,603 | I | Via wholly-owned subsidiary, Genzyme Corp. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Genzyme Corporation entered into a 60-day lock-up agreement (which may be extended under certain circumstances) which covers the shares acquired